Avatrombopag Maleate Drug Asset Due Diligence Report 2026

This Avatrombopag Maleate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

110

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Avatrombopag Maleate can convert its Small molecule drug profile and TPO receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Avatrombopag Maleate (query alias: avatrombopag)
Modality / target	Small molecule drug; TPO receptor; TPO receptor agonists
Highest global status	Approved
Originator	Astellas Pharma, Inc.
Active developers	Swedish Orphan Biovitrum AB, Swedish Orphan Biovitrum Japan KK, Sobi North America

The MCP disease footprint includes Chronic liver disease, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07278908	Phase 2/3	Not yet recruiting	248	Treatment Free Rate at week 52
JPRN-jRCT2011260012	Phase 2/3	募集前	9	A hematological response at Week 26 Definition of a hematological response: Achieving uni- or multilineage response by one or more of the following criteria: o Platelet response is defined as meeting at least one of the following criteria 1. Platelet count increase of >=2010^9/L from baseline; 2. Platelet count increase of >=1010^9/L with an increase of >=100% from baseline; or 3. Absence of platelet transfusions for 8 consecutive weeks in trial participants who had received platelet transfusions during the 8 weeks prior to the first avatrombopag dose. o Erythrocyte response is defined as meeting either of the following criteria 1. Baseline hemoglobin of <9.0 g/dL with an increase of >=1.5 g/dL from baseline (without RBC transfusions); or 2. Cumulative volume of RBC transfusion for 8 consecutive weeks is reduced by 800 mL in trial participants who had received RBC transfusions during the 8 weeks prior to first avatrombopag dose. o Neutrophil response is defined as meeting either of the following criteria 1. If baseline neutrophil <0.510^9/L, increase by >=100% from baseline; or 2. If baseline neutrophil <1.010^9/L, increase by >=0.5*10^9/L from baseline.
NCT07600905	Not Applicable	Completed	134	platelet rise rate

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Avatrombopag for chemotherapy-induced thrombocytopenia in gastrointestinal malignancies (ACT-GI): A multicenter, U.S., randomized, double-blind, placebo-controlled clinical trial.

Phase 2; n=47; evaluation: Positive. Reported fields: Platelets(The median (IQR) at the end of the on-cycle treatment period) = 72.0 ×10^9/L ; Platelets(The median (IQR) at the end of the on-cycle treatment period) = 157.0 ×10^9/L

PROSPECTIVE EVALUATION OF A MODIFIED AVATROMBOPAG INITIATION DOSE TO REDUCE PLATELET OVERSHOOTING IN IMMUNE THROMBOCYTOPENIA

Phase 4; n=28; evaluation: Positive. Reported fields: AE = 9.0 Pts

EFFICACY AND SAFETY OF AVATROMBOPAG IN THE MANAGEMENT OF PROLONGED CYTOPENIAS FOLLOWING CAR-T CELL THERAPY: A GETH-TC STUDY

Not Applicable; n=47; evaluation: Positive. Reported fields: AE = one case of grade 1 persisting nausea and another with grade 1 hepatitis, resolved with a 20 mg dose reduction

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Avatrombopag Maleate addresses Chronic liver disease, Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-01-29	Acino signs an exclusive distribution agreement with the Swedish biopharmaceutical company Sobi in Kazakhstan	Approved	Financial terms not disclosed
2022-09-15	Asahi Kasei Pharma and Swedish Orphan Biovitrum Japan conclude exclusive distribution agreement for pegcetacoplan	Approved	Financial terms not disclosed
2018-09-26	Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)	Approved	US$2.5M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Avatrombopag and new therapeutic use thereof”. The milestone feed surfaced a patent-application signal described as “Salts of avatrombopag”. The milestone feed surfaced a patent-application signal described as “Solid oral compositions of avatrombopag maleate”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO